Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
Immune response evaluation criteria in solid tumors (iRECIST) is recommended during immune checkpoint inhibitors (ICIs) treatment, due to the possibility of pseudoprogression. We evaluated the frequency of pseudoprogression in hepatocellular carcinoma (HCC) patients. This retrospective multicenter s...
Na minha lista:
| Principais autores: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021-12-01
|
| Serier: | Frontiers in Medicine |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/articles/10.3389/fmed.2021.771887/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|